# Efficacy and Safety of SPC1001 in Patients With Essential Hypertension

Study · id `cardio:ct-nct06826872` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06826872](<https://clinicaltrials.gov/study/NCT06826872>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06826872

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 252 participants.

## Technical summary

Registry record NCT06826872. Randomized; double masking; primary purpose treatment. Start 2024-06-12 (actual); primary completion 2025-10-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 252 participants (planned count; ClinicalTrials.gov record NCT06826872, source copy `cardio:ctgov-nct06826872-2025-02-14`, retrieved 2026-10-26)
- Started: 2024-06-12 (actual) (ClinicalTrials.gov record NCT06826872, source copy `cardio:ctgov-nct06826872-2025-02-14`, retrieved 2026-10-26)
- Primary completion: 2025-10-08 (anticipated) (ClinicalTrials.gov record NCT06826872, source copy `cardio:ctgov-nct06826872-2025-02-14`, retrieved 2026-10-26)
- Completion: 2025-12-30 (anticipated) (ClinicalTrials.gov record NCT06826872, source copy `cardio:ctgov-nct06826872-2025-02-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06826872, source copy `cardio:ctgov-nct06826872-2025-02-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06826872-2025-02-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
- Condition: Hypertension, Essential
- Condition: Cardiovascular Diseases
- Condition: Cardiology
- Intervention (Drug): SPC 1001 Mid2
- Intervention (Drug): SPC 2002
- Intervention (Drug): SPC 2003
- Intervention (Drug): SPC 2004
- Lead sponsor: Shin Poong Pharmaceutical Co. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shin Poong Pharmaceutical Co. Ltd. (`cardio:org-shin-poong-pharmaceutical-co-ltd`)

## Provenance

Content hash: cc09b74a60709c5d827c37e6032d227619bbdd0c8ffc1e1bc8188da14d2b2972
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
